

CURRICULUM VITAE

PERSONAL DATA

Name: Raymond Scott Turner

EDUCATION

09/1975-05/1979 Clemson University, S.C.; B.S. with Honor, Microbiology & Molecular Biology
09/1979-05/1984 Emory University, Atlanta, Ga.; Ph.D., Pharmacology (mentor: J.F. Kuo)
09/1984-05/1988 Emory University, Atlanta, Ga.; M.D.

POSTGRADUATE TRAINING

07/1988-06/1989 Intern, Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pa.
07/1989-06/1992 Resident/Assistant Instructor, Neurology, University of Pennsylvania Medical Center, Philadelphia
07/1992-06/1995 Research Fellow, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center
07/1992-06/1995 Fellow, Cognitive Neurology Section, Department of Neurology, Hospital of the University of Pennsylvania

ACADEMIC APPOINTMENTS

07/1995-08/2003 Assistant Professor, Department of Neurology, University of Michigan, Ann Arbor
07/1995- Attending Neurologist, Veterans Affairs Ann Arbor Healthcare System
07/1995- Research Scientist, Neuroscience Section, Geriatric Research Education and Clinical Center (GRECC), Veterans Affairs Ann Arbor Healthcare System
07/1996- Faculty, Neuroscience Graduate Program, University of Michigan
07/1999- Faculty, Program in Biomedical Sciences (PIBS), University of Michigan
08/2001-08/2003 Assistant Research Scientist, Institute of Gerontology, University of Michigan
09/2002- Chief, Neurology Service, Veterans Affairs Ann Arbor Healthcare System
09/2003- Associate Professor, Department of Neurology, University of Michigan
09/2003- Senior Associate Research Scientist, Institute of Gerontology, University of Michigan

SCIENTIFIC ACTIVITIES

1996- Reviewer, American Federation for Aging Research grants
1996- Reviewer, Neurology
1997- Reviewer, Journal of Clinical and Experimental Neuropsychology

1997 Reviewer, Archives of General Psychiatry
1997- Reviewer, Experimental Neurology
1998- Reviewer, Alzheimer's Association grants
1998- Reviewer, Annals of Neurology
1998- Editorial Board and Reviewer, Aging, Neuropsychology, and Cognition
1998- Reviewer, Journal of Biological Chemistry
1998- Reviewer, Journal of Clinical Investigation
1998- Reviewer, Veterans Affairs MERIT grants
1998 Reviewer, New England Journal of Medicine
2000 Reviewer, Nature Biotechnology
2000 Reviewer, Proceeding of the National Academy of Sciences
1999- Reviewer, Journal of Neurochemistry
2000 Reviewer, American Journal of Pathology
2000- Reviewer, Journal of the American Geriatrics Society
1999 Reviewer, Journal of the International Neuropsychologic Society
2001 Reviewer, American Geriatrics Society abstracts
2000- Reviewer, Human Molecular Genetics
2003 Reviewer, Epilepsy Research
2003- Reviewer, NIH grants
2003 Reviewer, Proceedings of the Indian National Science Academy (India)
2004 Reviewer, U.S. Civilian Research and Development Foundation grants
2004 Reviewer, Journal of Neuroscience
2004- Reviewer, Brain Research
2004- Reviewer, Alzheimer's Research Trust (U.K.) grants
2004- Reviewer, Brain
2005 Reviewer, Neuroscience
2005 Reviewer, Wellcome Trust (U.K.) grants
2005 Reviewer, Trends in Neurosciences
2006 Reviewer, Alzheimer's Disease and Associated Disorders

GRANT SUPPORT

Past

- 1992-1995 Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians, "Amyloid precursor protein processing in human CNS neuronal cells (NT2-N)", PI RS Turner, direct cost \$210,667 for 08/01/92-06/30/95.
- 1996-1997 Veterans Education and Research Association of Michigan (VERAM), "Amyloid Precursor Protein Processing in Neurons", total cost \$5,000 for 05/01/96-04/30/97 (declined).
- 1996-1997 Michigan Alzheimer's Disease Research Center (P50-AG-08671) and Institute of Gerontology/Nathan Shock Center, "Amyloid Precursor

- Protein in Human Neurons”, PI RS Turner, total cost \$10,000 for 06/01/96-05/31/97.
- 1996-1997 Warner-Lambert/Parke-Davis, “A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Milameline in Patients With Probable Alzheimer’s Disease with Long-Term Open Label Extension”, 0 % effort, PI NR Barbas, total cost \$216,780 for 06/03/96-12/31/98 (performed CIBICs).
- 1997-2002 NIH, Training in Basic and Clinical Neurosciences (T32-NS07222), PI S Gilman, Coinvestigator RS Turner, direct costs \$1,239,582 for 07/01/97-06/30/02.
- 1998-1999 Biomedical Research Council, Univ. of Michigan Medical School, “Inhibition of Amyloid Peptide Secretion by Endoplasmic Reticulum Chaperones”, 10 % effort, PIs JR Gaut & RS Turner, total cost \$25,000 for 02/01/98-01/31/99.
- 1998-2000 State of Michigan Department of Community Health, “Graduate Health Professions Training in Medicaid Managed Care”, 5 % effort, PI JO Wooliscroft, \$4,054,313 for 10/01/97-10/01/00.
- 2000-2001 Eisai, “A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease”, 0 % effort, PI NR Barbas (performed CIBICs).
- 1998-2001 American Federation for Aging Research, Paul B. Beeson Physician Faculty Scholars in Aging Research Award, “The Role of X11 α in Amyloid Precursor Protein Processing”, % effort not specified, PI RS Turner, total cost \$446,973 for 07/01/98-06/30/01.
- 2001 Summer Biomedical Fellowship Program, UROP, Univ. of Michigan, PI KE Benton & RS Turner, \$3,500 for 05/07/2001-08/24/01.
- 2001 Summer Biomedical Fellowship Program, UROP, Univ. of Michigan, PI CC Gan & RS Turner, \$3,500 for 05/07/2001-08/24/01.
- 2001 Janssen Pharmaceuticals, Educational Grant, “Pathways for More Effective Diagnosis and Treatment of Dementia” (CME course), \$16,850.
- 2001-2002 NIH/NIA, National Alzheimer’s Coordinating Center (2 UO1 AG16976), “Collaborative PET Imaging Study”, Site PI NL Foster, 5 % effort, total

cost \$125,000 (Univ. of Michigan) for 03/01/01-06/30/03.

- 2001-2002 Geriatrics Center/Institute of Gerontology, Univ. of Michigan, “Gene Expression Profiles in Brain of Tg2576 Alzheimer Mice: Effect of Aging, Amyloidogenesis, and Caloric restriction”, PI RS Turner, 5 % effort, \$33,000 for 05/01/01-06/30/02.
- 2002-2003 C.E.&S. Foundation, Inc., Lexington, Ky., \$42,500.
- 2002-2003 Forest Laboratories, “A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type”, 0 % effort, PI NR Barbas (performed CIBICs).
- 2003 The John. A. Hartford Foundation/AFAR Medical Student Geriatric Scholars Program, PI JN Stojan & RS Turner, \$4,000 for 06/01/03-07/31/03.
- 2002-2003 NIH/NIA, Michigan Alzheimer’s Disease Research Center (P50-AG-08671), Pilot Grant, PI SA Camper, “Transgenic Rat Models of Alzheimer’s Disease”, 5 % effort, direct cost \$30,000 for 07/01/02-06/30/03.
- 2001-2003 Alzheimer’s Association, “Effects of Amyloid Precursor Protein and X11 α /mint-1 Interaction”, PI RS Turner, 10 % effort, direct cost \$200,000 for 09/01/01-08/30/03.
- 2002-2003 NIH/NIA, Rush Alzheimer’s Disease Research Center, Pilot Grant, PI KB Cease, “Serum Proteases and Amyloid Peptide Aggregation”, 2 % effort, direct cost \$30,000 for 10/01/02-09/30/03.
- 2002-2004 Forest Laboratories, “A Long-Term Extension Study Evaluating the Safety and Tolerability of BID and QD Administration of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type”, 0 % effort, PI NR Barbas (performed CIBICs).
- 2001-2004 NIH/NINDS, Individual National Research Service Award (F30 43078-01), PI RS Turner and GD King, direct cost \$80,000 for 09/01/01-09/01/04.
- 1999-2004 NIH/NIA, Michigan Alzheimer’s Disease Research Center (P50-AG-08671), PI Project 4 RS Turner, “Protein-Protein Interactions in Amyloid Precursor Protein Processing”, 30 % effort, direct cost \$468,540 for 06/01/99-05/31/04.

- 1999-2005 NIH/NIA, Michigan Alzheimer's Disease Research Center (P50-AG-08671), PI NL Foster, "Clinical Core", 5 % effort, direct cost \$1,594,230 for 06/01/99-05/31/05.
- 2000-2005 NIH, Multidisciplinary Research Training in Aging (T32-AG00114-16), PI A Gafni, Coinvestigator RS Turner, direct cost \$2,508,604 for 05/01/00-04/30/05.
- Current*
- 2001-2006 NIH, Early Stage Training in the Neurosciences (T32-NS41227-01), PI RI Hume, Coinvestigator RS Turner, direct cost \$1,874,152 for 07/01/01-06/30/06.
- 2002-2007 NIH/NIA, Alzheimer's Disease Cooperative Study (U01-AG-010483), "Assessment Measures for AD Primary Prevention Trials", PI LJ Thal, Site PI RS Turner, 5 % effort, direct cost \$109,438 for 01/15/02-02/28/07.
- 2002-2007 NIH, Training in Basic and Clinical Neurosciences (T32-NS07222), PI EL Feldman, Coinvestigator RS Turner, direct cost \$1,351,546 for 07/01/02-06/30/07.
- 2003-2007 Veterans Affairs MERIT, "Engineered Vaccines for Alzheimer's Amyloid Deposition", PI KB Cease, Co-investigator RS Turner, 10 % effort, total cost \$540,000 for 4/01/03-03/30/07.
- 2005-2008 Elan Pharmaceutical Research Corporation, "AAB-001 in Patients with Mild to Moderate Alzheimer's Disease, A Phase II, Multicenter, Randomized, Placebo-controlled, Multiple ascending dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity trial", Site PI N Barbas, Coinvestigator RS Turner, 0 % effort, total cost \$218,548 for 03/23/05-04/30/08.
- 2005-2009 NIH/NIA, RO1 AG026916, "Genetic Associations with Alzheimer-free Survival", PI PL Kramer, Site PI RS Turner, 1 % effort, total cost \$38,250 (Univ. of Michigan site) for 09/15/05-06/30/09.
- 2005-2010 NIH/NIA, Multidisciplinary Research Training in Aging (T32-AG000114-21), PI R Miller, Coinvestigator RS Turner, direct cost \$2,508,604 for 05/01/05-04/30/10.
- 2005-2010 NIH/NIA, Michigan Alzheimer's Disease Research Center (P50-AG-08671), PI Project 1 RS Turner, "Modulation of APP metabolism by X11 α /mint-1", 10 % effort, direct cost \$625,000 for 07/01/05-06/30/10.

- 2005-2010 NIH/NIA, Michigan Alzheimer's Disease Research Center (P50-AG-08671), PI S Gilman, "Administrative Core", 2 % effort, direct cost \$523,593 for 07/01/05-06/30/10.
- 2005-2010 NIH/NIA, Michigan Alzheimer's Disease Research Center (P50-AG-08671), PI B Giordani, "Clinical Core", Coinvestigator RS Turner, 15 % effort, direct cost \$1,089,967 for 07/01/05-06/30/10.
- 2005-2010 NIH/NIA, Michigan Alzheimer's Disease Research Center (P50 AG08671) "Predicting Individual Rates of Progression in Alzheimer's Disease". PI Project 2 K Frey, Coinvestigator RS Turner, direct cost \$663,645 for 7/1/05-6/30/10.
- 2005-2010 NIH/NIA, Michigan Alzheimer's Disease Research Center (P50 AG08671) "Differentiating Degenerative Dementia with [¹¹C]DTBZ-PET Imaging", PI Project 3 RL Albin, Coinvestigator RS Turner, direct cost \$637,268 for 7/1/05-6/30/10.
- 2006-2007 University of Michigan Medical School Clinical Research Initiatives Program, "Nonlinear Dynamical Analysis of EEG and Biomarkers of Dementia, PI RS Turner, 5 % effort, direct cost \$73,165 for 07/01/06-06/30/07.
- 2006-2007 Wallace H. Coulter Translational Partners Grant Program, University of Michigan, "Functional screening of small molecules for inhibiting the ion channel activity of β -amyloid peptides", PI M Mayer, 10 % effort, Coinvestigator RS Turner, direct cost \$100,000 for 06/01/06-05/31/07.
- 2006-2010 VA Cooperative Studies Program (CSP # 546), "A Randomized, Multicenter, Double-blind, Placebo-Controlled trial of DL- α -tocopherol and Memantine for the Treatment of Functional Decline in Outpatients with Alzheimer's Disease on Donepezil", PI M Dysken, Site PI RS Turner, 06/01/06-12/31/10.

CERTIFICATION AND LICENSURE

- 1988-1995 Commonwealth of Pennsylvania
1988- DEA registration
1993- Diplomate in Neurology, American Board of Psychiatry and Neurology
1995- State of Michigan

HONORS AND AWARDS

- 1979-1982 NIH Predoctoral Pharmacological Sciences Training Grant

- 1982-1984 Tull Foundation Fellowship Award
1992-1995 Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians
1998-2001 Paul B. Beeson Physician Faculty Scholar in Aging Research
2001 Best Paper Award: Neurological and Behavioral Sciences, American Geriatrics Society Annual Meeting
2003-2005 Elected University of Michigan Councillor, Michigan Chapter, Society for Neuroscience
2005, 2006 Superior Performance Awards, VA Ann Arbor Healthcare System, for substantially exceeding performance requirements

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

American Association for the Advancement of Science
American Academy of Neurology
Society for Neuroscience
American Geriatrics Society
Central Society for Neurologic Research
Michigan Neurological Association
Michigan Chapter, Society for Neuroscience

TEACHING ACTIVITIES

Emory University

1981-1984 Lectures in pharmacology, and neurochemistry to medical, dental, and graduate students

University of Pennsylvania

1993-1994 Seminars in Alzheimer's Disease Research Center

1988-1995 Instructed and supervised medical students and house officers in neurology

1995 "A Causal Role of Amyloid Deposition in Alzheimer's Disease?", Grand Rounds, Department of Neurology

University of Michigan

1994 "Does Amyloid Cause Alzheimer's Disease?" Grand Rounds, Department of Neurology

1995- Attending Physician: Instruct and supervise medical students and house officers in neurology, Veterans Affairs and University of Michigan Medical Centers

1995- Bedside instruction and lectures in neurology to medical students rotating at the VA Ann Arbor Healthcare System

1995 "Neuronal Protein Processing", Basic Neuroscience Conference, Department of Neurology

1996 "Does Amyloid Cause Alzheimer's Disease?", Neurobehavioral Seminar Series, The Center for Enhancement and Restoration of Cognitive Function, School of Nursing

- 1996 “Alzheimer’s Disease Update”, Thursday Conference Series, Department of Neurology
- 1996 “The Mental Status Examination and Neuropsychologic Testing: Understanding the FAX”, Thursday Conference Series, Department of Neurology
- 1996 “Alzheimer’s Disease Update”, Geriatrics Research Conference, VA Ann Arbor Healthcare System GRECC
- 1996 “Depression, Pseudodementia and Dementia”, Pfizer Conference, Department of Psychiatry
- 1996-2004 “Aphasia and Apraxia” (annually), Neuroscience Sequence, Medical School
- 1996-1998 Thesis Committee, TR Neelands, Neuroscience Graduate Program
- 1997- Advisor/mentor to assigned neurology residents
- 1997 “Alzheimer’s Disease: A Neuroscience Perspective”, Neuroscience Program Seminar
- 1997 “Diagnosing Dementia and Alzheimer’s Disease”, Neurologic and Behavioral Issues in the Elderly, University of Michigan Continuing Medical Education Program
- 1997 “A Regulatory Role of X11 α in Amyloid Precursor Protein Processing”, Resident Education Research Seminar, Department of Neurology
- 1997 “Update on Molecular Mechanisms of Alzheimer’s Disease”, Michigan Alzheimer’s Disease Research Center and Satellites Symposium
- 1997- Journal Club, Molecular Mechanisms of Alzheimer’s Disease
- 1998 “Early Diagnosis of Alzheimer’s Disease”, Thursday Conference Series, Department of Neurology
- 1998 “The PTB Domain Protein X11 α Slows Amyloid Precursor Protein Processing and Reduces A β 40 and A β 42 Secretion. Implications for Alzheimer’s Disease?”, Institute of Gerontology
- 1998- Bedside instruction and lectures to medical students rotating in neurology at the University of Michigan Hospitals
- 1998 “A Case of Fluctuating Capgras’ Syndrome”, Grand Rounds, Department of Neurology
- 1998 “Alzheimer’s Disease Update”, Neuropsychology Section, Department of Psychiatry
- 1998 “Update on Alzheimer’s, Lewy Body, and Parkinson’s Diseases”, Grand Rounds, Department of Psychiatry
- 1998 Mentor, S Webster, visiting medical student
- 1998 “Therapeutic Use of Vitamins/Diet Supplements: What Should We Recommend to Our Patients?”, Geriatrics Clinical Conference
- 1998 “Alzheimer’s Disease: Past, Present, and Future”, summer geriatrics seminars for Hartford/AFAR medical students
- 1998-2000 Thesis Committee, WA Sherman, Biochemistry Graduate Program
- 1998-2000 Thesis Committee, JE Novak, Neuroscience Graduate Program
- 1998-2000 Thesis Advisor/Mentor, HT Mueller, Neuroscience Graduate Program

- 1998-2001 Thesis Committee, ML Steinhilb, Biochemistry Graduate Program
 1998 “Molecular Mechanisms of Alzheimer’s Disease”, Geriatrics Clinical Conference
 1999 Patient Presentation, Thursday Conference Series, Department of Neurology
 1999 “Evaluation of Patients with Dementia”, Noon Conference Series, Department of Internal Medicine
 1999 “Alzheimer’s Disease”, Clinical Neuroscience for Graduate Students and Staff (Neuroscience 731)
 1999 “Alzheimer’s Disease: Where Are We Now?”, Grand Rounds, Department of Neurology
 1999-2000 Thesis Committee, MC Talley, Neuropsychology Graduate Program
 1999-2003 Thesis Committee, GE Meyer, Neuroscience Graduate Program
 1999 “Lewy Body Dementia”, Parkinson’s Disease Update, University of Michigan Continuing Medical Education Program
 1999 “A Dementia Zoo”, Geriatrics Clinical Conference
 1999-2001 Mentor, CC Gan, Undergraduate Research Opportunity Program
 1999 “Post-stroke Rehabilitation”, GRECC Interdisciplinary Conference
 1999-2001 Mentor, J-T Gau, Geriatrics Fellow, Department of Internal Medicine
 2000 Patient Presentation, Thursday Conference Series, Department of Neurology
 2000 “Alzheimer’s Disease Anatomy, Pathology, Biology, Chemistry and Genetics”, Novartis Conference, College of Pharmacy
 2000-2003 Thesis Advisor/Mentor, GD King, Neuroscience Graduate Program
 2000-2001 Mentor, W Xu, Post-doctoral Fellow, Department of Neurology
 2000 “Update from the World Alzheimer Congress 2000”, Department of Neurology
 2000-2001 Mentor, FT Zaman, Undergraduate Research Opportunity Program
 2000 “Alzheimer’s Disease Research Orientation”, Geriatric Division, Department of Internal Medicine
 2000 Codirector with S Minoshima, Neuroscience 700 series on Alzheimer’s disease
 2000 “Therapeutic Strategies for Alzheimer’s Disease—Pharmacologic, Immunologic, or Genetic?”, Grand Rounds, Department of Neurology
 2001 Mentor, KE Benton, Undergraduate Research Opportunity Program
 2001 “The Role of X11 α in Amyloid Precursor Protein Processing, Diabetes Research and Training Center
 2001 “Treatment of Alzheimer’s Disease in the New Millennium—Pharmacologic, Immunologic, or Genetic?”, Institute of Gerontology
 2001 “Update on Dementia”, Grand Rounds, Department of Psychiatry
 2001 “Sometimes a Zebra is a Zebra: an Unusual Neurodegenerative Disease”, Patient Presentation, Department of Neurology
 2001 “Sometimes a Zebra is a Horse in Disguise: A Rare Presentation of a

- Common Neurodegenerative Disease”, Patient Presentation, Thursday Conference Series, Department of Neurology
- 2001 “Differential Diagnosis of Dementia”, Noon Conference Series, Geriatrics Division, Department of Medicine
- 2001-2002 Mentor, S Rabbani, Undergraduate Research Opportunity Program
- 2001-2003 Thesis Committee, A Meyer, Neuroscience Graduate Program
- 2001 “Lewy Body Dementia”, Geriatrics Division, Department of Medicine
- 2001-2003 “Research at the University of Michigan Department of Neurology”, Neurology Resident Applicants
- 2002 “Basic Science of Dementia for the Boards”, Department of Neurology
- 2002 “Evaluation of Dementia at the Turner Geriatrics Center”, Department of Medicine
- 2002 Mentor, A Narasimhan, Undergraduate Research Opportunity Program
- 2002 Journal Club, Department of Medicine, Geriatrics Division
- 2002 “Patient Presentation”, Thursday Conference Series, Department of Neurology
- 2002 “Project 4: Role of X11 α in APP Catabolism”, Department of Neurology
- 2002 “Dementias: Alzheimer’s Disease”, Department of Medicine
- 2002 “Dementias: Lewy Body Dementia and Parkinson’s Disease with Dementia”, Department of Medicine
- 2002 “Potential Role of X11 α in Inclusion Body Myositis”, Geriatrics Division, Department of Medicine and Institute of Gerontology
- 2002-2004 Mentor, I Saluja, Postdoctoral Fellow, Department of Neurology
- 2002- Thesis Committee, DJ Cross, Neuroscience Graduate Program
- 2002-2003 Mentor, KK Kuszpit, Neuroscience Graduate Program
- 2002 “Evaluation of Dementia at the Turner Geriatrics Center”, Department of Medicine
- 2002 “Regulation of Amyloid Precursor Protein Trafficking and Catabolism by Adaptor Protein Interactions”, Department of Medicine, Nephrology Division
- 2002 “Alzheimer’s Disease”, Clinical Neuroscience for Graduate Students and Staff (Neuroscience 731)
- 2002 Mentor, T Cheema, Neuroscience Graduate Program
- 2002 Mentor, A Haimerl, Undergraduate Research Opportunity Program
- 2003 Mentor, H Ho, Undergraduate Research Opportunity Program
- 2003 Mentor, G Budhrani, Undergraduate Research Opportunity Program
- 2003 “Patient Presentation”, Thursday Conference Series, Department of Neurology
- 2003 “Case Presentation and Discussion: Geriatric Neurology”, Geriatrics Division, Department of Internal Medicine
- 2003 Mentor, J Stojan, Medical Student Summer Research Program
- 2003-2005 Thesis Committee, AB Spillson, Neuroscience Graduate Program
- 2003-2004 Mentor, N Smith, Undergraduate Research Opportunity Program

- 2003-2004 Mentor, M Keat, Undergraduate Research Opportunity Program
2003-2004 Mentor, S Batts, Neuroscience Graduate Program
2004 “Differential diagnosis of dementia”, Geriatrics Division, Department of Internal Medicine
2004 “Sixty ways to cure Alzheimer’s disease—in mice?”, Department of Neurology
2004 Mentor, K Song, Undergraduate Research Opportunity Program
2004- Thesis Committee, M Heng, Neuroscience Graduate Program
2004 “Evaluation and treatment of Alzheimer’s disease”, Univ. of Michigan Continuing Medical Education Program
2004 “Contemporary management of Alzheimer’s Disease”, Mediterraneo (Pfizer), Ann Arbor
2004 Mentor, S Kotecha, Undergraduate Research Opportunity Program
2005 “Is amyloid the best target for therapy in Alzheimer’s disease?”, Dept. of Radiology, Division of Nuclear Medicine, Univ. of Michigan
2005 Mentor, Pharmacology 502
2005 Patient Presentation, Department of Neurology
2005 “Regulation of APP trafficking and processing by X11 α /mint-1”, Journal Club, Neurodegenerative diseases
2005 “Differential diagnosis of dementia”, Geriatrics Division, Department of Internal Medicine
2005 “Contemporary management of Alzheimer’s Disease”, Mediterraneo, Chop House, Mediterraneo (Pfizer), Ann Arbor
2005-2006 Mentor, O Adeniyi, Work-Study Program
2005-2006 Mentor, T Mohammadi, Undergraduate Research Opportunity Program
2005-2006 Mentor, J Bonilla-Larsen, Undergraduate Research Opportunity Program
2005 “Dementia Syndromes/Symptom Management”, Nursing School, Nursing 505, Bio-behavior I
2005 “Regulation of APP trafficking and processing by X11 α /mint-1”, Department of Neurology
2006 “Alzheimer’s disease for the Boards”, Department of Neurology
2006 Patient Presentation, Department of Neurology
2006 “Are we all Struldbruggs, or will aging research inform Alzheimer's disease therapeutics?”, Geriatrics Center/Institute of Gerontology
2006 “Vascular Dementia”, Dementia Conference, University of Michigan Continuing Medical Education Program

EXTRAMURAL INVITED PRESENTATIONS

- “Does Amyloid Cause Alzheimer’s Disease?”, Merck Research Laboratories, Rahway, N.J., March 3, 1995.
“Increased A β Secretion with Maturation of a Human Neuronal Cell Line”, Meeting of Predoctoral and Physician Postdoctoral Fellows, Howard Hughes Medical Institute, Chevy Chase, Md., June 7, 1995.

- “Alzheimer’s Disease: New Intervention and Practice Strategies, Pharmaceutical and Research Update”, Eighth Annual Continuing Education Program: Training on Issues in Aging, Troy, Mi. Sponsored by the Institute of Gerontology, Wayne State University, Detroit, Mi., May 20, 1996.
- “Regulation of Amyloid Precursor Protein Processing”, Parke-Davis/Warner-Lambert, Ann Arbor, Mi., August 23, 1996.
- “Update on the Treatment and Diagnosis of Alzheimer’s Disease in the Primary Care Setting”, Toledo, Oh., May 20, 1997, Ann Arbor, Mi., May 22, 1997, and Kalamazoo, Mi., November 19, 1997.
- “Update on Alzheimer’s Disease Research”, Michigan Milestones in Dementia Care: Update on Service, Education, Research and Policy, The Michigan Department of Community Health, Lansing, Mi., June 18, 1997.
- “Pathogenesis and Diagnosis of Alzheimer’s Disease”, Advanced Dementia Care, Eastern Michigan University, Ypsilanti, Mi., February 13, 1998.
- “Protein-Protein Interactions and Amyloid Precursor Protein Processing”, Parke-Davis/Warner-Lambert, Ann Arbor, Mi., October 8, 1998.
- “Protein-Protein Interactions and APP Processing: A Role in Alzheimer’s Disease?”, Medical College of Ohio, Toledo, Oh., October 22, 1998.
- “Update on Alzheimer’s Disease”, Northville Hospital, Mi., November 12, 1998.
- “Protein-Protein Interactions and APP Processing: A Role in Alzheimer’s Disease?”, University of Chicago, Chicago, Il., December 10, 1998.
- “Molecular Mechanisms of Alzheimer’s Disease”, Alpena, Mi., February 20, 1999.
- “Of Alzheimer’s Disease, APP, and X11”, Central Society for Neurologic Research, Pere Marquette, Il., September 18, 1999.
- “Alzheimer’s Disease: Fatal Attractions and Protein Interactions”, Wayne State University, Detroit, Mi., November 2, 1999.
- “Cognitive Disorders”, McLaren Hospital, Flint, Mi., December 3, 1999.
- “Modulation of Amyloid Precursor Protein Metabolism by the X11 α /mint-1 Family”, Co-Chair, “The Emerging Role of the Cytoplasmic Terminus of β APP in the Pathogenesis of Alzheimer’s Disease”, Biochemical Pharmacology Discussion Group Symposium, N.Y. Academy of Sciences, N.Y., N.Y., April 25, 2000.
- “The PTB Domain of X11/mint Interacts with the Cytoplasmic Terminus of APP and Modulates its Metabolism: Does the Tail Wag the Dog?”, Pfizer Central Research, Groton, Ct., August 25, 2000.
- “Progressive CNS Amyloidogenesis in Aging Human Amyloid Precursor Protein Swedish Mutation Transgenic Mice does not Induce Cholinergic Deficits”, American Geriatrics Society, Chicago, Il. May 10, 2001.
- “Parkinson’s Disease with Dementia and Lewy Body Dementia”, East Lansing, Mi., September 12, 2001.
- “Diagnosis When the Dementia is Not Alzheimer’s Disease”, Pathways to More Effective
Diagnosis and Treatment of Dementia, Livonia, Mi., November 3, 2001.

- “Stable β -secretase Activity and Presynaptic Cholinergic Function During Progressive CNS Amyloidogenesis in Tg2576 Mice”, Society for Neuroscience, San Diego, Ca., November 14, 2001.
- “A Tale of Two Proteins: A Role for Proteomics in Alzheimer’s Disease?”, Department of Neurology, Vanderbilt University, Nashville, Tn., March 1, 2002.
- “Update on Basic and Clinical Science of Dementia”, Alzheimer’s Association, Southfield, Mi., March 13, 2002.
- “Update on Basic and Clinical Science of Dementia and Alzheimer’s Disease”, Henry Ford Hospital, Detroit, Mi., June 21, 2002.
- “X11 α /mint-1 inhibits γ - but not β -secretase cleavage of the Swedish mutation of amyloid precursor protein (APP^{swe})”, Society for Neuroscience, Orlando, Fl., November 3, 2002.
- “X11 α /mint-1 inhibits γ -secretase cleavage of the amyloid precursor protein (APP) C-terminal fragment C99”, Society for Neuroscience, Orlando, Fl., November 3, 2002.
- “Regulation of Amyloid Precursor Protein Catabolism by Adaptor Protein Interactions”, Gerontologic Society of America, Boston, Ma., November 26, 2002.
- “REM sleep behavior disorder: an α -synucleinopathy predicting Lewy body dementia and Parkinson's disease?”, Case Western Reserve University, Cleveland, Oh., March 4, 2003.
- “Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?”, Case Western Reserve University, Cleveland, Oh., March 5, 2003.
- “Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?”, Emory University, Atlanta, Ga., May 22, 2003.
- “REM sleep behavior disorder: An α -synucleinopathy predicting Lewy body dementia and Parkinson's disease?”, Emory University, Atlanta, Ga., May 23, 2003.
- “Evaluation and Treatment of Dementia”, Great Lakes Nurses Association, Ann Arbor, Mi., January 14, 2004.
- “Adaptor proteins modulate amyloid precursor protein metabolism: Potential for gene therapy of Alzheimer’s disease?”, Cedars Sinai Medical Center/U.C.L.A., Los Angeles, Ca., February 24, 2004.
- “Regulation of amyloid precursor protein (APP) trafficking and processing by X11 α /mint-1 interaction”, American Academy of Neurology, San Francisco, Ca., April 29, 2004.
- “Sixty ways to cure Alzheimer’s disease—in mice”, Neurology/Neurosurgery/Psychiatry Grand Rounds, Medical College of Ohio, Toledo, Oh., 20 May, 2004.
- “Evaluation and treatment of dementia”, St. Vincent Mercy Medical Center, Toledo, Oh., 26 May, 2004.
- “X11 α /mint-1 modulates γ -cleavage of amyloid precursor protein”, The 9th International Congress on Alzheimer’s Disease and Related Disorders, Philadelphia, Pa., 21 July, 2004.

- “A randomized, double-blind, placebo-controlled trial of ibuprofen versus placebo in patients with mild-to-moderate dementia due to probable AD”, Alzheimer’s Disease Cooperative Studies, Atlanta, Ga., 29 January, 2005.
- “A phase II-a study to evaluate the impact of resveratrol treatment on biomarkers of Alzheimer’s disease (AD) in patients with mild-to-moderate dementia due to probable AD”, Alzheimer’s Disease Cooperative Studies Scientific Advisory Board, Atlanta, Ga. 30 January 2005; Chicago, Il., 23 March, 2005; Miami, Fl., 10 April, 2005; San Diego, Ca., 25 September, 2005; Las Vegas, Nv., 28 January, 2006; Bethesda, Md., 29 March, 2006.
- “The role of X11 α /mint1/APBA1 in amyloid precursor protein processing”, Georgetown Univ., Washington, D.C., 28 June, 2005.
- “Pharmacologic strategies for treatment of patients with Alzheimer’s disease”, Univ. of Toledo, Oh., 23 March, 2006.
- “What’s new in prevention and treatment of dementia and Alzheimer’s disease”, Univ. of Michigan Coast to Coast, Scottsdale, Az., 6 April, 2006; La Quinta, Ca., 7 April, 2006.
- “Future Directions in AD Research: Imaging, Biomarker and Treatment Targets”, Regional Conference, Lexington, Ky., 17 May, 2006.

COMMITTEE AND ADMINISTRATIVE SERVICE

National

- 2000 NIH/NIA site visit/review of Program Project Grant
- 2001- American Federation for Aging Research National Scientific Advisory Council
- 2003-2005 University of Michigan Councilor, Michigan Chapter, Society for Neuroscience (elected)
- 2003- NIH Scientific Review Group, Brain Disorders and Clinical Neuroscience, ZRG1 BDCN-E (11) SBIR

University of Michigan

- 1997- Interviewer, Neuroscience Graduate Program/PIBS
- 1997- Interviewer, Medical Scientist Training Program/PIBS
- 1999- Michigan Alzheimer’s Disease Research Center, Executive Committee
- 1999- Preliminary Examination Committee, Neuroscience Graduate Program
- 1999-2000 Admissions Committee, Program in Biomedical Sciences (PIBS)
- 1999-2001 Admissions Committee, Neuroscience Graduate Program
- 1999-2004 Neuroscience Committee, for Neuroscience Sequence, Medical School
- 2001 Course Planning Committee, Pathways to More Effective Diagnosis and Treatment of Dementia
- 2001-2002 Organizing Committee, Shock Center Workshop on Neurobiology of Aging
- 2003-2004 Faculty Recruitment Committee, Institute of Gerontology/Department of Physiology
- 2004- Michigan Alzheimer’s Disease Research Center, Clinical Core, Consensus

Committee
2005- Lucille Groff Professorship Search Committee

Department of Neurology, University of Michigan

1996-1997 Education Committee, Strategic Planning Retreat
1997-2000 Resident Selection Committee
1998- Executive Committee, Training Grant in Basic and Clinical Neurosciences
1999-2003 Faculty Recruitment Committee
2001-2002 Internal Review Committee, for Chair Selection Committee
2002- Appointments, Promotions and Awards Committee (APAC)
2006- Resident Education Committee

Veterans Affairs Ann Arbor Healthcare System

1998-2001 Research and Development Committee (ad hoc Chair)
2002- Clinical Executive Board
2002- Professional Standards Board
2002- Residency Review Committee
2002- Performance Improvement Committee
2002- Chief of Staff Advisory Committee
2002- Director's Staff Committee
2003- Ambulatory Care Utilization Committee
2005-2006 Search Committee, VA Ann Arbor GRECC Director
2005- Chair, Committee on Endovascular Treatment of Carotid Artery Stenosis

BIBLIOGRAPHY

Completed Publications in Scientific Journals

Peer-Reviewed Publications

1. Hosford DA, Haigler HJ, Turner RS: Methionine-enkephalin and morphine: amount ejected microiontophoretically. *J Neurosci Meth* 4: 135-139, 1981.
2. Wise BC, Glass DB, Chou C-HJ, Raynor RL, Katoh N, Schatzman RC, Turner, RS, Kibler RF, Kuo JF: Phospholipid-sensitive Ca^{2+} -dependent protein kinase from heart. II. Substrate specificity and inhibition by various agents. *J Biol Chem* 257: 8489-8495, 1982.
3. Turner RS, Chou C-HJ, Kibler RF, Kuo JF: Basic protein in brain myelin is phosphorylated by endogenous phospholipid-sensitive Ca^{2+} -dependent protein kinase. *J Neurochem* 39: 1397-1404, 1982.
4. Katoh N, Raynor RL, Wise BC, Schatzman RC, Turner RS, Helfman DM, Fain JN, Kuo JF: Inhibition by melittin of phospholipid-sensitive and calmodulin-sensitive Ca^{2+} -dependent protein kinases. *Biochem J* 202: 217-224, 1982.
5. Mazzei GJ, Qi D-F, Schatzman RC, Raynor RL, Turner RS, Kuo JF: Comparative abilities of lanthanide ions La^{3+} and Tb^{3+} to substitute for Ca^{2+} in regulating phospholipid-sensitive Ca^{2+} -dependent protein kinase and myosin light chain kinase. *Life Sciences* 33: 119-129, 1983.
6. Qi D-F, Schatzman RC, Mazzei GJ, Turner RS, Raynor RL, Liao S, Kuo JF: Polyamines

- inhibit phospholipid-sensitive and calmodulin-sensitive Ca^{2+} -dependent protein kinases. *Biochem J* 213: 281-288, 1983.
7. Kuo JF, Raynor RL, Mazzei GJ, Schatzman RC, Turner RS, Kem WR: Cobra polypeptide cytotoxin I and marine worm polypeptide cytotoxin A-IV are potent and selective inhibitors of phospholipid-sensitive Ca^{2+} -dependent protein kinase. *FEBS Letters* 153: 183-186, 1983.
 8. Turner RS, Raynor RL, Mazzei GJ, Girard PG, Kuo JF: Developmental studies of phospholipid-sensitive Ca^{2+} -dependent protein kinase and its substrates, and of phosphoprotein phosphatases in rat brain. *Proc Natl Acad Sci USA* 81: 3143-3147, 1984.
 9. Mazzei GJ, Schatzman RC, Turner RS, Vogler WR, Kuo JF: Phospholipid-sensitive Ca^{2+} -dependent protein kinase inhibition by R-24571, a calmodulin antagonist. *Biochem Pharmacol* 33: 125-130, 1984.
 10. Qi D-F, Turner RS, Kuo JF: S-100 and other acidic proteins promote Ca^{2+} -independent phosphorylation of protamine catalyzed by a new protein kinase from brain. *J Neurochem* 42: 458-465, 1984.
 11. Turner RS, Chou C-HJ, Mazzei GJ, Dembure P, Kuo JF: Phospholipid-sensitive Ca^{2+} -dependent protein kinase preferentially phosphorylates serine-115 of bovine myelin basic protein. *J Neurochem* 43: 1257-1264, 1984.
 12. Kuo JF, Schatzman RC, Turner RS, Mazzei GJ: Phospholipid-sensitive Ca^{2+} -dependent protein kinase: a major protein phosphorylation system. *Mol Cell Endocrinol* 35: 65-73, 1984.
 13. Turner RS, Kemp BE, Su H-D, Kuo JF: Substrate specificity of phospholipid/ Ca^{2+} -dependent protein kinase as probed with synthetic peptide fragments of the bovine myelin basic protein. *J Biol Chem* 260: 11503-11507, 1985.
 14. Su H-D, Kemp BE, Turner RS, Kuo JF: Synthetic myelin basic protein peptide analogs are specific inhibitors of phospholipid/calcium-dependent protein kinase (protein kinase C). *Biochem Biophys Res Comm* 134: 78-84, 1986.
 15. Wertkin AM, Turner RS, Pleasure SJ, Golde TE, Younkin SG, Trojanowski JQ, Lee VM-Y: Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular β -amyloid or A4 peptides. *Proc Natl Acad Sci USA* 90: 9513-9517, 1993.
 16. Turner RS, Kenyon LC, Trojanowski JQ, Gonatas N, Grossman M: Clinical, neuroimaging, and pathologic features of progressive non-fluent aphasia. *Annals Neurol* 39: 166-173, 1996.
 17. Turner RS, Suzuki N, Chyung ASC, Younkin SG, Lee VM-Y: Amyloids β_{40} and β_{42} are generated intracellularly in cultured human neurons and their secretion increases with maturation. *J Biol Chem* 271: 8966-8970, 1996.
 18. Cook DG, Turner RS, Kolson DL, Lee VM-Y, Doms RW: Vaccinia virus serves as an efficient vector for expressing heterologous proteins in human NTera 2 neurons. *J Comp Neurol* 374: 481-492, 1996.
 19. Turner RS, Chervin RD, Frey KA, Minoshima S, Kuhl DE: Probable diffuse Lewy body disease presenting as REM sleep behavior disorder. *Neurology* 49: 523-527, 1997.
 20. Neelands TR, Greenfield Jr LR, Zhang J, Turner RS, Macdonald RL: GABA_A receptor pharmacology and subtype mRNA expression in human neuronal NT2-N cells. *J Neurosci*

- 18: 4993-5007, 1998.
21. Borg J-P, Yang Y, De Taddeo-Borg M, Margolis B, Turner RS: The X11 α protein slows cellular amyloid precursor protein processing and reduces A β 40 and A β 42 secretion. *J Biol Chem* 273: 14761-14766, 1998.
 22. Sastre M, Turner RS, Levy E: X11 interaction with β -amyloid precursor protein modulates its cellular stabilization and reduces amyloid β -protein secretion. *J Biol Chem* 273: 22351-22357, 1998.
 23. Yang Y, Turner RS, Gaut JR: The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases A β 40 and A β 42 secretion. *J Biol Chem* 273: 25552-25555, 1998.
 24. Borg JP, Straight SW, Kaech SM, De Taddeo-Borg M, Kroon DE, Karnak D, Turner RS, Kim SK, Margolis B: Identification of an evolutionarily conserved heterotrimeric protein complex involved in protein targeting. *J Biol Chem* 273: 31633-31636, 1998.
 25. Borg JP, Lopez-Figueroa MO, de Taddeo-Borg M, Kroon DE, Turner RS, Watson SJ, Margolis B: Molecular analysis of the X11-mLin-2/CASK complex in brain. *J Neurosci* 19: 1307-1316, 1999.
 26. Novak JE, Turner RS, Agranoff BW, Fisher SK: Differentiated human NT2-N neurons possess a high intracellular content of myo-inositol. *J Neurochem* 72: 1431-1440, 1999.
 27. Turner RS, D'Amato CJ, Chervin RD, Blaivas M: The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. *Neurology* 55: 1730-1732, 2000.
 28. Mueller HT, Borg J-P, Margolis B, Turner RS: Modulation of amyloid precursor protein metabolism by X11 α /mint-1: A deletion analysis of protein-protein interaction domains. *J Biol Chem* 275: 39302-39306, 2000.
 29. Steinhilb ML, Turner RS, Gaut JR: The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by β -secretase. *J Biol Chem* 276: 4476-4484, 2001.
 30. Gau J-T, Steinhilb ML, Kao TC, D'Amato CJ, Gaut JR, Frey KA, Turner RS: Stable β -secretase activity and presynaptic cholinergic function during progressive CNS amyloidogenesis in Tg2576 mice. *Am J Pathol* 160: 731-738, 2002.
 31. Hong M, Shah GV, Adams KA, Turner RS, Foster NL: Spontaneous intracranial hypotension causing reversible dementia. *Neurology* 58: 1285-1287, 2002.
 32. Steinhilb ML, Turner RS, Gaut JR: ELISA analysis of β -secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. *J Neurochem* 80: 1019-1028, 2002.
 33. Ho CS, Marinescu V, Steinhilb ML, Gaut JR, Turner RS, Stuenkel EL: Synergistic effects of Munc18a and X11 proteins on APP metabolism. *J Biol Chem* 277: 27021-27028, 2002.
 34. Corcoran KA, Lu Y, Turner RS, Maren S: Overexpression of hAPP^{swe} impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. *Learning and Memory* 9: 243-252, 2002.
 35. King GD, Perez RG, Steinhilb ML, Gaut JR, Turner RS: X11 α modulates secretory and endocytic trafficking and processing of amyloid precursor protein: Mutational analysis of the YENPTY sequence. *Neuroscience* 120: 143-154, 2003.

36. Higdon R, Foster NL, Koeppe RA, DeCarli CS, Jagust WJ, Clark CM, Barbas NR, Arnold SE, Turner RS, Heidebrink JL, Minoshima S: A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging. *Stat Med* 23: 315-326, 2004.
37. King GD, Cherian K, Turner RS: X11 α inhibits γ - but not β -cleavage of amyloid precursor protein. *J Neurochem* 88: 971-982, 2004.
38. Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD, for the Alzheimer's Disease Cooperative Study: ADCS prevention instrument project: Assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. *Alz Dis Assoc Disorders*, in press, 2006
39. Patterson MB, Whitehouse PJ, Edland SD, Sami SA, Sano M, Smyth K, Weiner MF, for the Alzheimer's Disease Cooperative Study: ADCS prevention instrument project: Quality of Life Assessment (QOL). *Alz Disease Assoc Disorders*, in press, 2006.
40. Cummings JL, Raman R, Ernstrom K, Salmon D, Ferris SH, for the Alzheimer's Disease Cooperative Study. ADCS prevention instrument project: Behavioral measures in primary prevention trials. *Alz Disease Assoc Disorders*, in press, 2006.

Chapters in Books

1. Schatzman RC, Turner RS, Kuo JF: Phospholipid-sensitive Ca²⁺-dependent protein phosphorylation. In Cheung WY (ed): *Calcium and Cell Function 5* (Academic Press, Orlando, 1984), 33-66.
2. Turner RS, Qi D-F, Kuo JF: Developmental studies of phospholipid/Ca²⁺-dependent and S-100-modulated protein phosphorylation systems in brain. In O'Lague P (ed): *Neurobiology: Molecular Biological Approaches to Understanding Neuronal Function and Development* (AR Liss, NY, 1985), 101-111.
3. Turner RS, Kuo JF: Phospholipid-sensitive Ca²⁺-dependent protein kinase (protein kinase C): the enzyme, substrates and regulation. In Kuo JF (ed): *Phospholipids and Cellular Regulation 2*, (CRC Press, Boca Raton, FL, 1985), 75-110.
4. Kuo JF, Turner RS: Phospholipid/Ca²⁺-dependent protein kinase (protein kinase C) as effector and modulator for membrane signals: an overview. In Russo-Marie F, Menciahuerta JM, Chignard M (eds): *Advances in Inflammation Research 10* (Raven Press, NY, 1986), 63-71.
5. Kuo JF, Shoji M, Girard PR, Mazzei GJ, Turner RS, Su H-D: Phospholipid/calcium-dependent protein kinase (protein kinase C) system: a major site of bioregulation. In Weber G (ed): *Advances in Enzyme Regulation 25* (Pergamon Press, Oxford, 1986), 387-400.
6. Turner RS, Heidebrink JL: Behavioral Neurology. In Labanowski M (ed): *Neurology Pearls of Wisdom* (Boston Medical Publishing, 1998), 21-28.
7. Levy E, Sastre M, Turner RS: X11 modulation of β -amyloid precursor protein cellular stabilization and reduction of amyloid β -protein secretion. In Iqbal K, Swaab DF, Winblad B, Wisniewski HM (eds): *Alzheimer's Disease and Related Disorders. Etiology, Pathogenesis and Therapeutics* (Wiley, Chichester, 1999), 397-404.

8. Heidebrink JL, Turner RS: Behavioral Neurology. In Labanowski M (ed): Neurology Pearls of Wisdom, 2nd ed. (Boston Medical Publishing, 2001), 21-30.
9. Hedera P, Turner RS: Inherited Dementias. In Lynch DR, Farmer JM (eds): Neurologic Clinics of North America 20 (Saunders, Philadelphia, 2002), 779-808.
10. Turner RS: Neurological aspects of Alzheimer's disease. In Lichtenberg PA, Murman DL, Mellow AM (eds): Handbook of Dementia: Psychological, Psychiatric, and Neurological Perspectives (Wiley, Hoboken, N.J., 2003), 1-24.
11. Heidebrink JL, Turner RS: Behavioral Neurology. In Labanowski M (ed): Neurology Pearls of Wisdom, 3rd ed. (Boston Medical Publishing, 2004), in press.
12. Turner RS: Alzheimer's disease. In Lynch DR (ed): Neurogenetics: Scientific and Clinical Advances (Taylor and Francis, N.Y., N.Y., 2006), 643-661.

Reviews and Invited Reviews

1. Turner RS: Alzheimer's disease in man and transgenic mice: females at higher risk. Am J Pathol 158: 797-801, 2001.
2. Turner RS: Rapid eye movement sleep behavior disorder is a harbinger of dementia with Lewy bodies. J Geriatr Psychiat Neurol 15: 195-199, 2002.
3. Turner RS: Biomarkers of Alzheimer's disease and mild cognitive impairment: Are we there yet? Exp Neurol 183: 7-10, 2003.
4. King GD, Turner RS: Adaptor protein interactions: Modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? Exp Neurol 185: 208-219, 2004.
5. Turner RS: Alzheimer's disease. Seminars in Neurol, in press, 2006.

Invited Case Report Summaries

1. Turner RS, D'Amato CJ, Chervin RD, Blaivas M: The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Dementia Review Series (Stockholm) 4: 14-15, 2001.
2. Hong M, Shah GV, Adams KA, Turner RS, Foster NL: Spontaneous intracranial hypotension causing reversible dementia. Dementia Review Series (Stockholm) 5: 9-11, 2003.

Book Review

1. Turner RS, Bieliauskas LA: Hanin I, Yoshida M, Fisher A (eds): Alzheimer's and Parkinson's Diseases: Recent Developments, Advances in Behavioral Biology 44, J Chem Neuroanat 11: 285-286, 1996.

Editorial

1. Bieliauskas LA, Turner RS: What Persian Gulf War syndrome? The Clinical Neuropsychologist 14: 341-343, 2000.

Letters

1. "Feedback" to "An End to Alzheimer's?", Technology Review 104:19-21, 2001.
2. Reply to Letter to Hong M, Shah GV, Adams KA, Turner RS, Foster NL: Spontaneous

intracranial hypotension causing reversible dementia. *Neurology* 59: 787, 2002.

Website Development

1. "New frontiers in battle against Alzheimer's", Alliance for Aging Research, Newsletter 12, 2002.
2. "Alzheimer's disease", American Federation for Aging Research, 2002.

Panel Discussions (Public Forum Presentations)

1. "What's New in Prevention of Memory Disorders", Dancey House, Chelsea, MI, 2006.
2. "A Discussion on Alzheimer's Disease", after matinee performance of *Moonglow*, Performance Network, Ann Arbor, MI, 2006.
3. "Prevention of Memory Disorders", Turner Senior Resource Center, Ann Arbor, MI, 2006.

Abstracts

1. Wise BC, Glass DB, Katoh N, Chou C-HJ, Schatzman RC, Turner RS, Raynor RL, Kibler RF, Kuo JF: Substrate specificity of phospholipid-sensitive Ca^{2+} -dependent protein kinase (PL-Ca-PK) from heart and spleen. *Fed Proc* 41: 3510, 1982.
2. Turner RS, Chou C-HJ, Kibler RF, Kuo JF: Phospholipid-sensitive Ca^{2+} -dependent protein kinase is involved in protein phosphorylation in central nervous system myelin. *Fed Proc* 41: 3511, 1982.
3. Qi D-F, Turner RS, Kuo JF: S-100 stimulates protamine phosphorylation catalyzed by a new protein kinase from brain. *Fed Proc* 42: 2870, 1983.
4. Mazzei GJ, Raynor RL, Schatzman RC, Turner RS, Qi D-F, Kuo JF: Polymyxin B and R-24571 (an imidazolium) inhibit both phospholipid-sensitive and calmodulin-sensitive Ca^{2+} -dependent protein kinases. *Fed Proc* 42: 3574, 1983.
5. Qi D-F, Schatzman RC, Mazzei GJ, Turner RS, Raynor RL, Liao S, Kuo JF: Inhibition by polyamines of phospholipid-sensitive Ca^{2+} -dependent protein kinase (PL-Ca-PK) and myosin light chain kinase (MLCK). *Fed Proc* 42: 3559, 1983.
6. Turner RS, Raynor RL, Chou C-HJ, Kemp BE, Kibler RF, Kuo, JF: Phosphorylation of myelin basic protein (MBP) and its fragments and peptides by phospholipid-sensitive Ca^{2+} -dependent protein kinase (PL-Ca-PK) and cAMP-dependent protein kinase (A-PK). *Fed Proc* 42: 3558, 1983.
7. Kuo JF, Raynor RL, Schatzman RC, Mazzei GJ, Turner RS, Kem WR: Polypeptide cytotoxins and neurotoxins differentially inhibit phospholipid-sensitive Ca^{2+} -dependent protein kinase (PL-Ca-PK) and myosin light chain kinase (MLCK). *Fed Proc* 42: 3557, 1983.
8. Kuo JF, Turner RS, Qi D-F: Developmental studies of phospholipid/ Ca^{2+} -dependent and S-100 protein-modulated protein phosphorylation systems in brain. *J Cell Biochem, Suppl* 8B: 1094, 1984.
9. Turner RS, Chou C-HJ, Mazzei GJ, Dembure P, Kuo JF: Phospholipid-sensitive Ca^{2+} -dependent protein kinase (PL-Ca-PK) preferentially phosphorylates serine-115 of bovine myelin basic protein (MBP). *Fed Proc* 43: 300, 1984.
10. Wertkin AM, Turner RS, Pleasure SJ, Golde TE, Younkin SG, Trojanowski JQ, Lee VM-Y:

- Neurons derived from a human cell line secrete β /A4 peptides and express a unique profile of potentially amyloidogenic carboxy-terminal fragments. Soc for Neurosci 19: 397, 1993.
11. Turner RS, Lee VM-Y: Neurons derived from a human teratocarcinoma cell line generate intracellular A β prior to its secretion into conditioned medium. Soc for Neurosci 20: 1244, 1994.
 12. Cook DG, Turner RS, Lee VM-Y, Doms RW: Efficient expression of foreign proteins in a human neuronal tissue culture system. Soc for Neurosci 20: 1332, 1994.
 13. Suzuki N, Cheung TT, Turner RS, Cai X-D, Odaka A, Otvos L Jr, Gillespie SL, Ho L, Shoji M, Eckman C, Golde TE, Lee VM-Y, Younkin SG: The familial amyloid β protein precursor (β APP717) mutations increase production of long amyloid β protein. Neurobiol of Aging 15: S54, 1994.
 14. Turner RS, Kenyon LC, Trojanowski JQ, Gonatas N, Reivich M, Grossman M: Clinical, neurodiagnostic, and pathologic features of two patients with progressive non-fluent aphasia (PNFA). Neurol 45: A357, 1995.
 15. Turner RS, Lee VM-Y: Increased A β secretion with maturation of a human neuronal cell line. Meeting of Predoctoral and Physician Postdoctoral Fellows, Howard Hughes Medical Institute, 42, 1995.
 16. Elmer LW, Turner RS: Expression and characterization of *huntingtin* in N-tera2 neurons. International Congress on Movement Disorders 11: 47, 1996.
 17. Greenfield LJ Jr, Neelands TR, Zhang J, Turner RS, Macdonald RL: Human teratocarcinoma-derived neuronal NT2-N cells express functional GABA_A receptors and mRNA encoding GABA_A receptor subunits. Soc for Neurosci 22: 1941, 1996.
 18. Neelands TR, Turner RS, Macdonald RL: Human teratocarcinoma-derived neuronal NT2-N cells contain ω -CGTX-GVIA and nifedipine sensitive Ca²⁺ currents. Soc for Neurosci 22: 345, 1996.
 19. Greenfield LJ Jr, Neelands TR, Turner RS, Macdonald RL: Human teratocarcinoma-derived neuronal NT2-N cells express functional GABA_A receptors regulated by convulsant and anticonvulsant drugs. Epilepsia 37, Suppl 5: 42, 1996.
 20. Turner RS, Chervin RD, Frey KA, Minoshima S, Kuhl DE: Probable diffuse Lewy body disease presenting as rapid eye movement sleep behavior disorder. Annals Neurol 42: 401, 1997.
 21. Neelands TR, Zhang J, Greenfield J, Turner RS, Macdonald RL: GABA_A receptors expressed in human teratocarcinoma NT2 stem cells differ from those expressed by differentiated neuronal NT2-N cells. Soc for Neurosci 23: 957, 1997.
 22. Greenfield LJ Jr, Turner RS, Macdonald RL: Human clonal NT2-N neurons express voltage-gated sodium currents sensitive to anticonvulsants. Soc for Neurosci 23: 1477, 1997.
 23. Turner RS, Borg JP, Yang Y, De Taddeo-Borg M, Margolis B: The YENPTY-binding protein X11 α slows cellular APP processing and inhibits APPs, A β 40, and A β 42 secretion. Neurol 50: A233, 1998.
 24. Levy E, Sastre M, Turner RS: X11 modulation of β -amyloid precursor protein cellular stabilization and reduction of β -protein secretion. Neurobiol of Aging 19: S215, 1998.
 25. Turner RS, Yang Y, Gaut JR: The chaperone BiP/GRP78 binds to amyloid precursor protein

- and decreases A β 40 and A β 42 secretion. *Neurobiol of Aging* 19: S104, 1998.
26. Novak JE, Turner RS, Agronoff BW, Fisher SK: Myo-inositol homeostasis in differentiated NT2-N neurons. *Soc for Neurosci* 24: 113, 1998.
 27. Minoshima S, Paulson P, Rosenberg B, Morrow TJ, Turner RS, Casey KL: Human forebrain rCBF correlates of perceived heat intensity pain threshold and tolerance. *Soc for Neurosci* 24: 1129, 1998.
 28. Gaut JR, Steinhilb ML, Turner RS: Differential BiP binding identifies potential A β peptide substrates in the endoplasmic reticulum. *Molecular Mechanisms of Alzheimer's Disease, FASEB J*: in press, 1999.
 29. Steinhilb ML, Turner RS, Gaut JR: Mutant BiP inhibits ER retrograde transport of amyloid precursor protein (APP). *Protein Folding, Degradation and Molecular Chaperones, FASEB J*: in press, 1999.
 30. Turner RS, Borg J-P, Yang Y, Steinhilb ML, Gaut JR, Margolis B: X11 α and BiP/GRP78 modulate amyloid precursor protein metabolism and the secretion of A β peptides. *Fourth Annual Meeting of Paul Beeson Physician Faculty Scholars*, 1999.
 31. Mueller HT, Borg J-P, Margolis B, Turner RS: Modulation of amyloid precursor protein metabolism by X11 α /mint-1. A deletion analysis of protein-protein interaction domains. *Neurobiol of Aging* 21: S256, 2000.
 32. Turner RS, D'Amato CJ, Chervin RD, Blaivas M: The pathology of REM sleep behavior disorder with Lewy body dementia: More than coincidence. *Neurobiol of Aging* 21: S16, 2000.
 33. Steinhilb ML, Turner RS, Gaut JR: Quantitative evaluation of β -secretase cleavage of amyloid precursor protein in the secretory and endocytic pathways. *Neurobiol of Aging* 21: S115, 2000.
 34. Mueller HT, Borg J-P, Margolis B, Turner RS: Modulation of amyloid precursor protein metabolism by X11 α /mint-1. A deletion analysis of protein-protein interaction domains. *Fifth Annual Meeting of Paul Beeson Physician Faculty Scholars*, 2000.
 35. Gau J-T, Desmond TJ, Frey KA, Turner RS: Vesicular acetylcholine transporter binding is preserved in hAPP^{swe} transgenic mouse brain. *Soc for Neurosci* 26: 2044, 2000.
 36. Gau J-T, Desmond TJ, Austin LL, Lu Y, Cherian K, Kao T-C, D'Amato CJ, Frey KA, Turner RS: Progressive CNS amyloidogenesis in aging human amyloid precursor protein Swedish mutation transgenic mice does not induce cholinergic deficits. *J Amer Geriat Soc* 49: S2, 2001.
 37. King GD, Perez RG, Steinhilb ML, Gaut JR, Turner RS: The -YXNP- tetrapeptide of amyloid precursor protein (APP) is required for endocytosis and for X11 α /mint-1 interaction. *Sixth Annual Meeting of Paul Beeson Physician Faculty Scholars*, 2001.
 38. Turner RS, Gau J-T, Steinhilb ML, Kao T-C, D'Amato CJ, Gaut JR, Frey KA: Stable β -secretase activity and presynaptic cholinergic function during progressive CNS amyloidogenesis in Tg2576 mice. *Sixth Annual Meeting of Paul Beeson Physician Faculty Scholars*, 2001.
 39. Xu W, Dozmorov IM, Lu Y, Miller RA, Turner RS: Gene expression profiles in brain of wild type and Tg2576 mice. *Sixth Annual Meeting of Paul Beeson Physician Faculty*

- Scholars, 2001.
40. King GD, Perez RG, Steinhilb MS, Gaut JR, Turner RS: The –YXNP– tetrapeptide of amyloid precursor protein (APP) is required for endocytosis and for X11 α /mint-1 interaction. *Soc for Neurosci* 27: in press, 2001.
 41. Turner RS, Gau J-T, Steinhilb ML, Kao TC, D’Amato CJ, Gaut JR, Frey KA: Stable β -secretase activity and presynaptic cholinergic function during progressive CNS amyloidogenesis in Tg2576 mice. *Soc for Neurosci* 27: in press, 2001.
 42. Corcoran KA, Lu Y, Turner RS, Maren S: Learning and memory in a transgenic mouse model of Alzheimer’s disease. *Soc for Neurosci* 27: in press, 2001.
 43. Ho CS, Marinescu V, Bewick K, Gaut JR, Turner RS, Stuenkel EL: Effects of mint proteins and munc18A on APP metabolism. *Soc for Neurosci* 27, in press, 2001.
 44. Hong M, Shah G, Adams K, Turner RS, Foster NL: Spontaneous intracranial hypotension causing reversible dementia. *Neurology* 58: A380, 2002.
 45. Foster NL, Poynter JA, Heidebrink JL, Jagust WJ, Clark CM, Turner RS, Barbas NR, Arnold SE, DeCarli C, Koeppe RA, Higdon R, Minoshima S: Good diagnostic inter-rater reliability in a multicenter study of FDG-PET in the evaluation of dementia. *Neurology* 58: A401, 2002.
 46. King GD, Perez RG, Steinhilb ML, Gaut JR, Turner RS: X11 α /mint-1 inhibits γ - but not β -secretase cleavage of the Swedish mutation of amyloid precursor protein. *Seventh Annual Meeting of Paul Beeson Physician Faculty Scholars*, 2002.
 47. Gau J-T, Steinhilb ML, Kao T-C, D’Amato CJ, Gaut JR, Frey KA, Turner RS: Stable β -secretase activity and presynaptic cholinergic markers during progressive CNS amyloidogenesis in Tg2576 mice. *Neurobiol of Aging* 23, S250, 2002.
 48. Turner RS, Cherian K, King GD: X11 α /mint-1 inhibits γ -secretase cleavage of the amyloid precursor protein C-terminal fragment C99. *Neurobiol of Aging* 23, S193, 2002.
 49. King GD, Steinhilb ML, Perez RG, Gaut JR, Turner RS: X11 α /mint-1 inhibits γ - but not β -secretase cleavage of amyloid precursor protein. *Neurobiol of Aging* 23, S185, 2002.
 50. Lu Y, Corcoran KA, King GD, Furay AR, Margolis B, Albin RL, Saunders TL, Maren S, Turner RS: In vivo modulation of APP catabolism in brain and enhanced learning and memory in human X11 α transgenic mice. *Neurobiol of Aging* 23, S240, 2002.
 51. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S: Inter-rater reliability and diagnostic accuracy of FDG-PET is superior to clinical history and examination in dementia. *Neurobiol of Aging* 23, S353, 2002.
 52. King GD, Steinhilb ML, Gaut JR, Turner RS: X11 α /mint-1 inhibits γ - but not β -secretase cleavage of the Swedish mutation of amyloid precursor protein (APP^{swe}). *Soc for Neurosci* 28, in press, 2002.
 53. Turner RS, Cherian K, King GD: X11 α /mint-1 inhibits γ -secretase cleavage of the amyloid precursor protein (APP) C-terminal fragment C99. *Soc for Neurosci* 28, in press, 2002.
 54. Turner RS: Regulation of amyloid precursor protein catabolism by adaptor protein interactions. *The Gerontologist* 42, 402, 2002.
 55. Higdon R, Foster NL, Koeppe RA, DeCarli CS, Jagust WJ, Clark CM, Barbas NR, Arnold

- SE, Turner RS, Heidebrink JL, Minoshima S: A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging, Stat Med, in press, 2003.
56. King GD, Cherian K, Turner RS: X11 α inhibits γ - but not β -secretase mediated cleavage of amyloid precursor protein. Soc for Neurosci 29, in press, 2003.
 57. Turner RS, Verhey KJ, King GD: A critical role for tyrosine 743 of amyloid precursor protein trafficking and metabolism. Soc for Neurosci 29, in press, 2003.
 58. Saluja I, Lu Y, Saunders T, Turner RS: Regulatory roles of X11 α /mint-1 in neurons. Soc for Neurosci 29, 523.4, 2003.
 59. Foster NL, Koeppe RA, Rogers V, Minoshima S, Clark CM, Jagust WJ, Arnold SA, Barbas NR, DeCarli CS, Heidebrink JL, Turner RS: A multi-center trial to evaluate the clinical utility of FDG-PET. Neurobiol of Aging 25, 246, 2004.
 60. Turner RS, King GD, Saluja I, Lu Y, Cherian K, Saunders TL: Regulation of amyloid precursor protein (APP) trafficking and processing by X11 α /mint-1 interaction. Neurology 62, A522, 2004.
 61. Heidebrink JL, Barbas NR, Turner RS, Clark CM, Jagust WJ, Arnold SE, DeCarli CS, Koeppe RA, Higdon R, Foster NL: FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous. Neurobiol of Aging 25, S370-371, 2004.
 62. Foster NL, Barbas NR, Heidebrink JL, Turner RS, Clark CM, Jagust WJ, Arnold SE, DeCarli CS, Koeppe RA, Higdon R, Minoshima S: Adding FDG-PET to clinical information improves the accuracy of dementia diagnosis. Neurobiol of Aging 25, S372, 2004.
 63. Turner RS, Saluja I, Lu Y, Saunders T: X11 α /mint-1 modulates γ -cleavage of amyloid precursor protein. Neurobiol of Aging 25, in press, 2004.
 64. Heidebrink JL, Arnold SE, Barbas NR, Clark CM, DeCarli CS, Jagust WJ, Turner RS, Higdon R, Koeppe RA, Foster NL: Diagnostic confidence in the clinical diagnosis of frontotemporal dementia and Alzheimer's disease. Annals Neurol 56, S19, 2004.
 65. Turner RS, Saluja I, Saunders TL: Modulation of neuronal APP metabolism by X11 α /mint-1/APBA-1. Neurobiol of Aging, in press, 2006.

Acknowledgments (for patient diagnosis, management, and recruitment)

1. Mittl RL Jr, Yousem DM: Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. Am J Neuroradiol 15: 633-638, 1994.
2. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficarò EP, Foster NL, Frey KA, Kilbourn MR: In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurol 52: 691-699, 1999.
3. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Annals Neurol 48: 391-395, 2000.
4. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K: Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Annals Neurol 55: 774-780, 2004.

5. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordano B, Persad C, Heumann M, Wernette K: Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [¹⁸F]fluorodeoxyglucose and neuropsychological testing. *Exp Neurol* 191 Suppl 1: S95-S103, 2005.
6. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL: ¹¹C-DTBZ and ¹⁸F-FDG PET measures in differentiating dementias. *J Nuc Med* 46: 936-944, 2005.
7. Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR: In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. *Ann Neurol* 59: 13-20, 2006.

4/4/2006 1:44 PM